Fund Holdings — JOHNSON & JOHNSON

Total Portfolio Value:
$4.41B
Total Bought:
$36.02M
Total Sold:
$1.91M
Net Transaction:
+$34.11M
Securities
▲▼
SharesValue
Q4 2023
▲▼
Q1 2024
▲▼
Change
▲▼
Q4 2023
▲▼
Q1 2024
▲▼
Weight (%)
▲▼
Change
▲▼
Kenvue Inc.(KVUE)182,329,550182,329,5500$3.93B$3.91B88.66%-$12.76M
Fusion Pharmaceuticals Inc.3,670,5163,670,5160$35.27M$78.26M1.77%+$42.98M
CVRx, Inc.(CVRX)3,495,5754,103,430+607,855$109.90M$74.72M1.69%-$35.18M
Protagonist Therapeutics Inc.2,449,1832,449,1830$56.16M$70.85M1.61%+$14.70M
Shockwave Medical, Inc.166,812166,8120$31.79M$54.32M1.23%+$22.53M
Legend Biotech CorporationADS(LEGN)814,586814,5860$49.01M$45.69M1.04%-$3.32M
MeiraGTx Holdings plc(MGTX)6,641,0646,641,0640$46.62M$40.31M0.91%-$6.31M
Nanobiotix S.A.ADS(NBTX)5,623,8165,623,8160$40.94M$36.55M0.83%-$4.39M
Neumora Therapeutics, Inc.(NMRA)1,849,4451,849,4450$31.53M$25.43M0.58%-$6.10M
Fate Therapeutics, Inc.(FATE)3,379,0643,379,0640$12.64M$24.80M0.56%+$12.16M
PROCEPT BioRobotics Corporation(PRCT)357,939357,9390$15.00M$17.69M0.40%+$2.69M
Xencor, Inc.(XNCR)748,062748,0620$15.88M$16.55M0.38%+$673.3K
Arrowhead Pharmaceuticals, Inc.(ARWR)247,598247,5980$7.58M$7.08M0.16%-$495.2K
Vor Biopharma Inc.(VOR)1,074,6581,074,6580$2.42M$2.55M0.06%+$129.0K
Nano-X Imaging Ltd.
ORD SHS
317,704158,852-158,852$2.02M$1.55M0.04%-$471.8K
Aldeyra Therapeutics, Inc.(ALDX)299,669299,6690$1.05M$979.9K0.02%-$71.9K
Tessera Defense and Homeland Security Inc.(HLSQ)2,133,4021,923,201-210,201$597.4K$865.4K0.02%+$268.1K
Adicet Bio, Inc.688,595364,472-324,123$1.30M$856.5K0.02%-$444.9K
Standard BioTools Inc.(LAB)0311,967+311,967$0$845.4K0.02%+$845.4K
Clearside Biomedical, Inc.169,629169,6290$198.5K$259.5K0.01%+$61.1K
Tracon Pharmaceuticals, Inc.84,00384,0030$14.7K$36.1K0.00%+$21.4K
Senseonics Holdings, Inc.(SENS)54,62154,6210$31.1K$29.0K0.00%-$2.1K
Apollomics, Inc.CL A(APLM)13,2520-13,252$12.8K$0—-$12.8K
SomaLogic, Inc.281,0520-281,052$711.1K$0—-$711.1K
Page 1 of 1
JOHNSON & JOHNSON — 13F Holdings — Q1 2024 | TickerTrail